Azasteroid Compound Combination for Tuberculosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis (TB) treatments are lengthy, toxic, and require daily monitoring, leading to challenges in compliance and the development of drug-resistant strains, with a need for new therapeutic agents to address multi-drug, extensively-drug, and totally-drug resistant TB strains, as well as latent infections.
Innovation Solution
A compound with a specific structure is administered in combination with anti-tuberculosis drugs to enhance bactericidal activity and reduce treatment duration and toxicity, potentially including isoniazid, bedaquiline, or other TB drugs, to treat TB infections effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current TB treatment regimens are used, then TB disease can be treated, but treatment duration is excessively long and toxicity is high
Solution Approach 1:
The patent employs a two-phase treatment strategy where an initial intensive phase (2 months) uses high doses of multiple drugs including the novel compound to rapidly reduce bacterial load, followed by a continuation phase (4 months) with lower doses. This preliminary aggressive action shortens overall treatment duration while maintaining effectiveness.
Solution Approach 2:
The patent modifies treatment parameters by introducing a novel azasteroid compound with different pharmacokinetic and pharmacodynamic properties than existing drugs. This allows for optimized dosing regimens that maintain efficacy while reducing total treatment duration and toxicity through altered drug metabolism and bacterial killing kinetics.
2Reliability
If current TB treatment regimens are used, then TB disease can be treated, but toxicity is high and compliance is difficult
Solution Approach 1:
The patent combines the novel azasteroid compound with existing first-line TB drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) in a composite regimen. This composite approach leverages the synergistic effects of multiple mechanisms of action to achieve effective treatment while allowing for reduced doses of individually toxic drugs, thereby lowering overall toxicity.
Solution Approach 2:
The novel azasteroid compound acts as an intermediary agent that enhances the bactericidal activity of existing TB drugs through synergistic interactions. This mediator effect allows for reduced dosages of conventional drugs, thereby decreasing their associated toxicities while maintaining or improving overall treatment effectiveness.
3Reliability
If current TB treatment regimens are used, then TB disease can be treated, but drug resistance develops
Solution Approach 1:
The novel azasteroid compound provides multi-functionality by targeting multiple bacterial pathways and exhibiting activity against both replicating and non-replicating Mycobacterium tuberculosis populations. This multi-target mechanism reduces the likelihood of resistance development compared to single-target drugs, as bacteria would need to develop multiple simultaneous resistance mechanisms.
Solution Approach 2:
The combination regimen incorporating the novel compound creates a composite therapeutic approach with multiple mechanisms of action. This diversity in molecular targets and killing mechanisms makes it significantly harder for bacteria to develop resistance, as simultaneous mutation at multiple independent targets is statistically improbable.
4Adaptability or versatility
If MDR-TB treatment is used, then drug-resistant TB can be treated, but treatment complexity and cost increase
Solution Approach 1:
For MDR-TB, the patent employs an intensive initial phase where the novel compound is combined with second-line drugs to rapidly reduce bacterial load and establish control. This preliminary aggressive treatment simplifies subsequent continuation phases, reducing overall treatment complexity compared to traditional prolonged multi-drug regimens.
Solution Approach 2:
The introduction of the novel azasteroid compound with its unique pharmacological profile allows for optimized dosing parameters and treatment schedules for MDR-TB. This enables simplified regimens with fewer drugs or shorter durations compared to traditional MDR-TB treatment, reducing complexity while maintaining effectiveness.
Data Source
AI summary
The present invention provides a compound having the structure:for use in combination with an anti-tuberculosis drug for treating a subject infected with M. tuberculosis.